MK3475-365

About this trial

Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)

Patient Profile

For Patients with Metastatic Castrate Resistant Prostate Cancer (mCRPC).

Where’s this trial being run?

Tallaght University Hospital

Can I join this study / trial?

The first step we recommend is to talk to your doctor or the cancer trials team at your hospital. You can find contact details for cancer trials research units in Ireland here.

It’s also a good idea to print this page and bring it with you to your appointment. It can help guide the conversation and remind you of what to ask. You may also want to talk to your family or friends about your options, as they can offer support as you make decisions.

For more detailed information

Click Here

Questions?

Here’s a list of questions you may have for your doctor or local cancer research team.

Questions

---

Summary Data

Name:	MK3475-365
Number:	21-20
Full Title:	Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)

Principal Investigator:	Prof. Ray McDermott
Type:	Industry Sponsored
Sponsor:	Merck Sharp & Dohme LLC
Recruitment Started:	Global: Ireland:

Global Recruitment Target:
Ireland Recruitment Target:	4